. They identified 55 genes that were upregulated in metastatic tumors relative to localized ones, and found that the gene encoding the polycomb-group protein Enhancer of zeste homolog 2 (EZH2) was significantly upregulated in metastatic cells and correlated with cancer progression. Disruption of EZH2expression by RNAi caused growth inhibition and growth arrest at the G2-to M-phase transition in the cell cycle. Overexpression of EZH2 in cancer cells caused repression of a subset of genes, and this required the EZH2 'SET' domain and endogenous histone deacetylase activity.
